XML 96 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information
 6 Months Ended
Jun. 30, 2013
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Note 15: Segment Information
We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes.
 
Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2013
 
2012
 
2013
 
2012
Segment revenue — to unaffiliated customers:
 
 
 
 
 
 
 
Human pharmaceutical products:
 
 
 
 
 
 
 
Neuroscience
$
2,004.5

 
$
1,824.5

 
$
3,853.4

 
$
3,728.2

Endocrinology
1,784.3

 
1,704.1

 
3,509.2

 
3,395.1

Oncology
808.1

 
846.8

 
1,572.3

 
1,650.6

Cardiovascular
731.3

 
646.9

 
1,425.3

 
1,284.9

Other pharmaceuticals
58.0

 
66.2

 
129.1

 
140.9

Total human pharmaceutical products
5,386.2

 
5,088.5

 
10,489.3

 
10,199.7

Animal health
543.5

 
512.2

 
1,042.4

 
1,003.0

Total segment revenue
$
5,929.7

 
$
5,600.7

 
$
11,531.7

 
$
11,202.7

Segment profits:
 
 
 
 
 
 
 
Human pharmaceutical products
$
1,430.7

 
$
1,049.3

 
$
2,778.8

 
$
2,280.9

Animal health
147.7

 
136.4

 
277.0

 
263.9

Total segment profits
$
1,578.4

 
$
1,185.7

 
$
3,055.8

 
$
2,544.8

Reconciliation of total segment profits to consolidated income before taxes:
 
 
 
 
 
 
 
Segment profits
$
1,578.4

 
$
1,185.7

 
$
3,055.8

 
$
2,544.8

Other profits (losses):
 
 
 
 
 
 
 
Income related to transfer of exenatide commercial rights (Note 4)
—

 
—

 
495.4

 
—

Asset impairments, restructuring, and other special charges (Note 5)
(63.5
)
 
—

 
(85.2
)
 
(23.8
)
Total consolidated income before taxes
$
1,514.9

 
$
1,185.7

 
$
3,466.0

 
$
2,521.0


For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global service centers, certain acquisition-related transaction costs, and inventory valuation adjustments.